Zomedica Corp Stock Price, News & Analysis

Zomedica (OTCQB:ZOMDF) announced on January 23, 2026 that its TRUVIEW® digital microscopy system now includes AI diagnostic interpretation for hematology, with skin and ear cytology support to follow shortly. The software-based enhancement is available immediately to existing TRUVIEW subscribers via an over-the-air update through the myZomedica® ecosystem, requiring no new hardware. Zomedica says the AI classifies blood cells, flags abnormalities, and delivers results in minutes, while offering optional telepathology review by board-certified pathologists. The update aims to speed workflows, improve consistency, and leverage the installed base to expand the platform's clinical and commercial relevance.

Zomedica (OTCQB:ZOMDF) entered a contract manufacturing and services agreement with Rahm Sensor Development to produce the Cell-Guardian™, Rahm's first commercial personnel monitoring device. Zomedica will provide manufacturing, engineering services, and Level One customer support, aiming to monetize existing assets, improve utilization, and generate incremental contract-based revenue without increasing fixed costs. The company cited wearable market data (global market ~$84B in 2024, projected to $186B by 2030, CAGR 13.6%) as supportive of measured diversification into adjacent monitoring and sensor markets.

Zomedica (OTCQB: ZOMDF) will host the next installment of its investor webinar series, Fourth Friday at Four, on January 23, 2026 at 4:00 p.m. ET. Titled "Digital Advantage: Powering Scalable Growth Through Innovation," the session will outline Zomedica's expanding digital ecosystem, technology-enabled product pipeline, and initiatives aimed at driving sustainable revenue expansion, operating leverage, and long-term shareholder value. The program includes prepared remarks and a Q&A; investors can register online.

Zomedica (OTCQB:ZOMDF) launched the VETGuardian PLUS monitor on December 30, 2025, the next generation of its Zero Touch patient monitoring platform for veterinary clinics.

Key features include a built-in kennel display, remote clinic-wide viewing, live video with night vision and thermal imaging, flexible mounting, and a more robust design. The product is commercially available immediately in the United States and select international markets through direct sales and distributors.

Market context: Research and Markets estimates the global veterinary monitoring market at approximately $720 million in 2025 with an 8% CAGR through 2029. Zomedica offers an optional upgrade path for existing customers while continuing support and training.

Waste Energy Corp (OTCQB:WAST) secured USMCA certification and cleared U.S. customs for its patent-pending waste-to-energy conversion technology, with the majority of components en route to its Midland, Texas facility and remaining certified parts due in the first week of January 2026. Installation and commissioning will begin the first week of January, with the system expected to be fully operational by the end of January, positioning the company to enter a revenue generation phase in Q1 2026. The Midland site will convert non-recyclable plastics and tires into fuel, carbon materials, and monetizable environmental assets intended as a repeatable U.S. blueprint.

Zomedica (OTCQB: ZOMDF) announced a collaboration with Prime Video to feature its Assisi and Calmer Canine products in the new romantic comedy Merv, now streaming on Prime Video as of December 11, 2025.

The placement will be supported by coordinated digital, social, and educational campaigns aimed at pet parents, veterinarians, and investors to raise awareness of Zomedica's pet wellness technologies and their real-world applications.

Zomedica (OTCQB:ZOMDF) launched the TRUFORMA Progesterone assay on December 4, 2025, expanding its TRUFORMA point-of-care diagnostic menu into equine reproductive health. The assay delivers immediate, in-clinic progesterone results to support breeding programs, pregnancy monitoring, and therapeutic decisions.

Key points: the TRUFORMA suite now includes ACTH, insulin with automatic dilution, cortisol, and progesterone; the global equine reproductive technologies market was valued at $485M in 2024 and is projected to reach $845M by 2031 (CAGR ~8.1%). The assay is available via myZomedica or customer service.

Zomedica (OTCQB: ZOMDF) announced a special session of its "Fourth Friday at Four" investor webinar to be held on Friday, November 21, 2025 at 4:00 p.m. Eastern Time to provide strategic context for its product platforms, a review of third-quarter 2025 performance, and execution priorities for the remainder of 2025 and entry into 2026. The session will feature prepared remarks followed by a Q&A and a replay will be available after the event. Registration is open at the provided link for investors and stakeholders.

Zomedica (OTCQB: ZOMDF) announced it has earned ISO 13485:2016 certification for its manufacturing and distribution operations in Plymouth, Minnesota and Roswell, Georgia on November 6, 2025. The certification followed an independent audit validating conformity with medical device quality-management requirements across design, production, risk management, servicing, and regulatory compliance.

Management said the certification strengthens quality infrastructure, supports global market readiness and regulatory filings, enhances customer and partner confidence, promotes operational efficiency, and positions Zomedica to scale diagnostics and therapeutics — including potential products for the human health market.